Scientists decry NIH's decision to end remdesivir study as 'a lost opportunity'


Most scientists agree the National Institute of Allergy and Infectious Diseases, one of the 27 branches that make up the National Institutes of Health, faced a difficult decision when it decided to end a coronavirus treatment study early and begin giving remdesivir to patients assigned to receive a placebo after finding that the antiviral drug reduced recovery time. The call has received a lot of support, especially because it was made during a pandemic, and NIAID, considering it a moral imperative, has no regrets, Stat News reports. But there are some holdouts.
Steven Nissen, a trialist and cardiologist at the Cleveland Clinic, and Peter Bach, the director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center, don't think recovery time reduction should have been the deciding factor. Instead, they say, the study should have continued until the NIAID was able to collect more data on mortality — the survival rate for coronavirus patients enrolled in the trial wasn't statistically significant when the study ended. "The question is: Was there a route, or is there a route, to determine if the drug can prevent death?," said Nissen.
Without getting a clearer answer to that question, he said, the study is a "lost opportunity."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The NIAID's clinical director, H. Clifford Lane, has a counter argument. He wants to know how "many patients would we want to put at risk of dying" to finalize a more complete study. Read more at Stat News.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Sea lion proves animals can keep a beat
speed read A sea lion named Ronan beat a group of college students in a rhythmic dance-off, says new study
-
Humans heal much slower than other mammals
Speed Read Slower healing may have been an evolutionary trade-off when we shed fur for sweat glands
-
Novel 'bone collector' caterpillar wears its prey
Speed Read Hawaiian scientists discover a carnivorous caterpillar that decorates its shell with the body parts of dead insects
-
Scientists find hint of alien life on distant world
Speed Read NASA's James Webb Space Telescope has detected a possible signature of life on planet K2-18b
-
Katy Perry, Gayle King visit space on Bezos rocket
Speed Read Six well-known women went into lower orbit for 11 minutes
-
Scientists map miles of wiring in mouse brain
Speed Read Researchers have created the 'largest and most detailed wiring diagram of a mammalian brain to date,' said Nature
-
Scientists genetically revive extinct 'dire wolves'
Speed Read A 'de-extinction' company has revived the species made popular by HBO's 'Game of Thrones'
-
Dark energy may not doom the universe, data suggests
Speed Read The dark energy pushing the universe apart appears to be weakening